Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
BridgeBio Soars
BridgeBio Soars After Drug Gets Nod in Serious Heart Condition
BridgeBio Pharma Inc. jumped in premarket trading after its drug got US regulators’ nod to treat a deadly form of heart disease, paving the way for head-to-head competition with medications from Pfizer Inc.
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.
US FDA approves BridgeBio's drug for rare heart condition (Nov 22)
(This Nov. 22 story has been corrected to fix the list price of Pfizer's drug to about $268,000, not $225,000, in paragraph 3) (Reuters) - The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition,
BioSpace
1h
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
ETF Daily News
11h
BridgeBio Pharma (NASDAQ:BBIO) Receives FDA Approval for ATTR-CM Treatment ‘Attruby™ (acoramidis)’
To support patients,
BridgeBio
will provide Attruby free for life to U.S. clinical trial participants. The company has also ...
FiercePharma
1d
Look out, Pfizer: BridgeBio scores 'best-case' FDA nod for Attruby in cardiomyopathy
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
19h
BridgeBio Selects PANTHERx® Rare Specialty Pharmacy for Distribution of Attruby™ (acoramidis)
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
2d
BridgeBio: Next Chapter Begins After Attruby Approval
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
devdiscourse
3d
Revolutionary Drug Approvals and Global Health Updates
The latest health news highlights BridgeBio's new heart drug approved by the FDA, novel findings in breast cell research, ...
23h
BridgeBio price target raised to $45 from $42 at BofA
BofA raised the firm’s price target on BridgeBio (BBIO) to $45 from $42 and keeps a Buy rating on the shares after the company announced the FDA approved its stabilizer acoramidis as Attruby for ...
4d
BridgeBio Pharma trading halted, news pending
Pharma trading halted, news pendingDon't Miss our Black Friday Offers:Unlock your investing potential with TipRanks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Attruby
Food and Drug Administration
Pfizer
BBIO
Amyloidosis
Feedback